The evolving landscape of HIV drug resistance diagnostics for expanding testing in resource-limited settings

Seth C. Inzaule, Raph L. Hamers, Roger Paredes, Chunfu Yang, Rob Schuurman, Tobias F.Rinke de Wit

    Research output: Contribution to journalReview articleResearchpeer-review

    13 Citations (Scopus)


    © 2017, Publicaciones Permanyer. All rights reserved. Global scale-up of antiretroviral treatment has dramatically changed the prospects of HIV/AIDS disease, rendering life-long chronic care and treatment a reality for millions of HIV-infected patients. Affordable technologies to monitor antiretroviral treatment are needed to ensure long-term durability of limited available drug regimens. HIV drug resistance tests can complement existing strategies in optimizing clinical decision-making for patients with treatment failure, in addition to facilitating population-based surveillance of HIV drug resistance. This review assesses the current landscape of HIV drug resistance technologies and discusses the strengths and limitations of existing assays available for expanding testing in resource-limited settings. These include sequencing-based assays (Sanger sequencing assays and nextgeneration sequencing), point mutation assays, and genotype-free data-based prediction systems. Sanger assays are currently considered the gold standard genotyping technology, though only available at a limited number of resource-limited setting reference and regional laboratories, but high capital and test costs have limited their wide expansion. Point mutation assays present opportunities for simplified laboratory assays, but HIV genetic variability, extensive codon redundancy at or near the mutation target sites with limited multiplexing capability have restricted their utility. Next-generation sequencing, despite high costs, may have potential to reduce the testing cost significantly through multiplexing in high-throughput facilities, although the level of bioinformatics expertise required for data analysis is currently still complex and expensive and lacks standardization. Web-based genotype-free prediction systems may provide enhanced antiretroviral treatment decision-making without the need for laboratory testing, but require further clinical field evaluation and implementation scientific research in resource-limited settings.
    Original languageEnglish
    Pages (from-to)179-189
    JournalAIDS Reviews
    Issue number4
    Publication statusPublished - 1 Oct 2017


    • Antiretroviral therapy
    • Diagnostics
    • Drug resistance
    • HIV-1
    • Monitoring
    • Resource-limited settings


    Dive into the research topics of 'The evolving landscape of HIV drug resistance diagnostics for expanding testing in resource-limited settings'. Together they form a unique fingerprint.

    Cite this